The impact of surgery on patients with Von Hippel-Lindau-associated tumors: an international patient survey
The Oncologist · 2025
DOI: 10.1093/oncolo/oyaf206 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2025. Verfasst von Murali Sundaram und 5 weiteren Autor:innen. Beteiligte Einrichtung: Merck & Co. Inc., Rahway, NJ 07065, United States. Hauptthemen laut MEDLINE: von Hippel-Lindau Disease, Carcinoma, Renal Cell, Kidney Neoplasms, Pancreatic Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck Sharp & Dohme LLC, Merck & Co., Inc..
Abstract (Originalsprache)
Background
Von Hippel-Lindau syndrome (VHL) is a rare hereditary neoplastic disorder caused by mutations in the VHL gene. Treatment options for patients are limited to multiple surgeries dispersed between regular scans, watchful waiting, and treatments that preserve organ function.
Methods
An international, cross-sectional survey comprising patients in the United States (USA), Canada (CA), the United Kingdom (UK), France (FR), and Germany (DE) was conducted. Patients were recruited via the VHL Alliance; data were collected between Dec 2021 and May 2022. For inclusion, patients must have renal cell carcinoma, pancreatic neuroendocrine tumors, and/or central nervous system hemangioblastoma.
Results
In all, 220 patients (68.2% female, median age 40.0, median disease duration 15.8 years) in the USA (n = 108), CA (n = 37), the UK (n = 21), FR (n = 3), and DE (n = 51) completed the study. In this sample, n = 205 (93.2%) patients had experienced surgery; n = 171 (77.7%) had experienced multiple surgeries (median number of surgeries, 4.0); 166 (n = 75.5%) patients recorded data on their most recent surgery. Of these, patients reported that their most recent surgery worsened (scored 1-3) their fatigue (51.8%, n = 86), mental health (51.2%, n = 85), and ability to go about daily life (45.2%, n = 75). Approximately, 47.3% (n = 104) of patients selected reducing the number of surgeries as a top treatment goal, whereas 73% (n = 161) of patients indicated they would prefer to take a pill which would possibly delay the time until surgery.
Conclusion
Surgery negatively impacts the lives of patients, leading to a worsening in their fatigue, mental health, and ability to go about daily life.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Merck & Co. Inc., Rahway, NJ 07065, United States.
- Adelphi Real World, Bollington, SK10 5JB, United Kingdom.
- VHL Alliance, Boston, MA 02132, United States.
- Massachusetts General Hospital Center of Cancer Research and Harvard Medical School, Boston, MA 02114, United States.
ORCID-Profile: Christian Atkinson, Othon Iliopoulos
Förderung
- Merck Sharp & Dohme LLC
- Merck & Co., Inc.
Zitieren
APA
Sundaram, M., Atkinson, C., Cooper, C., Taylor-Stokes, G., Mann, J., & Iliopoulos, O. (2025). The impact of surgery on patients with Von Hippel-Lindau-associated tumors: an international patient survey. The Oncologist. https://doi.org/10.1093/oncolo/oyaf206
Vancouver
Sundaram M, Atkinson C, Cooper C, Taylor-Stokes G, Mann J, Iliopoulos O. The impact of surgery on patients with Von Hippel-Lindau-associated tumors: an international patient survey. The Oncologist. 2025. doi:10.1093/oncolo/oyaf206
BibTeX
@article{Sundaram2025,
author = {Sundaram, Murali and Atkinson, Christian and Cooper, Charley and Taylor-Stokes, Gavin and Mann, Joshua and Iliopoulos, Othon},
title = {The impact of surgery on patients with Von Hippel-Lindau-associated tumors: an international patient survey},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyaf206}
}
EUVIMED